Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Data Tables: PHEMCE MYB FY 2018-2022 Figures

PHEMCE-Wide Findings

Threat-based Approaches

Data Table for Figure 1. Estimated PHEMCE Spending by Portfolio and Fiscal Year

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
Pandemic Influenza $563  $828  $519  $2,028  $1,759
Broad Spectrum Antimicrobials $658  $696  $707  $808  $830
Cross-Cutting Science $594  $617  $535  $583  $617
Other Threats $562  $585  $503  $591  $530
Anthrax $393  $449  $229  $512  $696
Rad/Nuc $352  $292  $346  $505  $536
Filoviruses $376  $359  $324  $385  $442
Smallpox $239  $241  $297  $ 289  $707
Chemical $ 130  $102  $ 250  $735  $ 387
SNS Non-Procurement $184  $263  $ 239  $246  $ 254
FDA Regulatory Science $142  $141  $154  $173  $178
Multiplex Diagnostics $103  $107  $ 92  $ 95  $98
BARDA Mgt & Admin $92  $94  $60  $85  $85
BARDA MCIP $ 7  $39  $ 55  $ 150  $150
BARDA EID $  -  $  -  $  -  $200  $200
Botulinum $16  $54  $ 4  $ 29  $29
CIADM $  -  $  -  $  -  $75  $50
Ancillary $ 17  $5  $11  $37  $28
Plague/Tularemia $ 9  $  9  $8  $ 8  $8
Biodiagnostic  $  -  $  -  $  -  $  -  $40
Burkholderia $1  $ 1  $2  $ 2  $2
FMS $0  $0  $0  $0  $0

 


Portfolio Investments across NIH, ASPR, and FDA

Data Table for Figure 2. MCM Estimated Spending by High-Priority Portfolio and HHS Division for FYs 2018–2022

Portfolio ASPR BARDA ASPR
SNS
NIH
Anthrax$1,183$1035$61
Botulinum$111$0$21
Broad Spectrum Antimicrobials$1,446$0$2,253
Chemical$1,167$207$229
Filoviruses$1,393$0$493
Pandemic Influenza$3,832$527$1,337
Plague/  Tularemia$0$0$41
Rad/Nuc$1,616$191$223
Smallpox$394$1,325$54


Appendix A

Data Table for Figure 3. Estimated NIH MCM Spending by Portfolio, FYs 2018–2022 (dollars in millions)

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
Cross-Cutting Science $579  $601  $ 523 $ 538 $ 552
Other Threats $562 $ 585 $503  $ 516 $ 530
Broad Spectrum Antimicrobials $441  $496  $ 427  $ 438  $ 450
Pandemic Influenza$248 $ 298  $257  $ 263 $ 271
Multiplex Diagnostics$ 103 $107  $ 92 $ 95 $ 98
Filoviruses$ 103  $107 $ 92  $ 95  $ 97
Chemical$ 49  $ 49 $ 42 $ 43 $ 45
Rad/Nuc $48  $ 48 $ 41 $ 42 $ 44
Anthrax $13  $ 13 $11 $ 12 $ 12
Smallpox $11 $ 12 $ 10  $ 10 $ 11
Plague/Tularemia $ 9  $ 9  $ 8 $8 $ 8
Botulinum$ 4  $4  $ 4 $ 4  $4

 


Data Table for Figure 4. Estimated BARDA MCM Spending by Portfolio, FYs 2018–2022 (dollars in millions)

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
Pandemic Influenza$ 267  $ 505 $ 253 $ 1,542 $ 1,266
Rad/Nuc$ 294 $ 239 $ 293 $ 380  $ 410
Broad Spectrum Antimicrobials$ 216 $ 200 $ 280 $ 370 $  380
Filoviruses$ 274 $ 252 $ 232 $ 290 $  345
Anthrax$ 138 $ 280 $ 180 $ 285 $ 300
Chemical$ 51 $ 36 $ 100 $ 665 $  315
BARDA Mgt & Admin$ 92 $ 94 $ 60  $ 85 $ 85
BARDA MCIP$ 7 $ 39 $ 55  $ 150 $ 150
BARDA EID$  -    $  -    $  -   $ 200 $  200
Smallpox$ 148  $ 91 $ 85 $ 30 $  40
Cross-Cutting Science $ 15 $ 16 $ 12 $ 45  $ 65
CIADM $   -    $  -    $  -   $ 75 $ 50
Botulinum$ 11  $  50  $  -   $  25 $25
Other Threats $  -    $  -    $  -   $ 75  $  -  
Biodiagnostic $  -    $   -    $  -    $ -   $ 40

 

 

 

Data Table for Figure 5. Estimated BARDA ARD MCM Spending by Portfolio, FYs 2018–2022 (dollars in millions)

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
Broad Spectrum Antimicrobials$ 216  $ 140 $ 180 $ 230 $ 230
Rad/Nuc $ 113 $  135  $ 138 $ 180 $ 210
Chemical$ 51 $  36 $ 60 $ 465 $ 115
BARDA Mgt & Admin$ 92 $ 94 $  60 $ 85 $ 85
BARDA MCIP$ 7 $ 39 $ 55 $ 150 $ 150
BARDA EID $  -   $  -   $  - $ 200 $ 200
Filoviruses$ 19  $ 58 $ 32 $ 40 $ 75
Cross-Cutting Science$ 15 $ 16 $ 12 $ 45 $ 65
Anthrax$  15 $  26 $  10 $ 35 $ 50
CIADM $  -  $  -  $  - $ 75 $ 50
Smallpox$ 9  $ 18 $ 15 $ 30  $ 40
Other Threats $  -  $  -  $  - $ 75  $  - 
Botulinum $  -  $  -  $  - $ 25 $ 25

 

 

Data Table for Figure 6. Estimated BARDA PBS MCM Spending by Portfolio, FYs 2018–2022 (dollars in millions)

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
Filoviruses$ 255 $ 194 $ 200 $  250  $ 270
Anthrax $ 123 $ 254 $ 170 $  250 $ 250
Rad/Nuc$ 182 $ 104 $ 155 $  200 $ 200
Broad Spectrum Antimicrobials $  - $  60 $ 100 $ 140 $ 150
Chemical $ 1  $  - $ 40 $ 200 $  200
Smallpox $ 139 $ 73 $  70  $  -  $  - 
Botulinum$ 11 $ 50  $  -  $  -  $  - 
Biodiagnostic $  -  $  -  $  -  $  - $ 40

 


Data Table for Figure 7. Estimated BARDA Pandemic Influenza MCM Spending by Portfolio, FYs 2018–2022 (dollars in millions)

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
Vaccine Advanced Development$ 75 $ 43 $  60 $  661 $ 525
Facilities, Infrastructure Readiness, and Sustainability$ 95 $ 278 $ 90 $  264 $  172
Therapeutics Advanced Development$ 49 $ 98 $  55 $ 234  $ 204
Ventilators/Respirators Advanced Development $  - $ 20 $ 20 $ 221 $  221
Vaccine Stockpile, Storage, Stability, and Testing$ 11 $ 66 $ 28 $ 146 $ 129
Diagnostics Advanced Development$ 24  $  -  $  -  $  -  $  - 
International MCM and Sample Testing Initiative $  -  $  -  $  - $ 10 $ 10
MCM Innovation$ 10  $  -  $  - $ 5 $ 5
Fill/Finish Network$  3  $  -  $  -  $  -  $  - 

 


Table for Figure 8. Estimated SNS MCM Spending by Portfolio, FYs 2018–2022 (dollars in millions)

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
Smallpox$ 80 $ 138 $ 202 $  249 $ 657
Anthrax$ 242 $ 156 $  38 $   215 $ 384
SNS Non-Procurement$ 184 $ 263 $  239 $ 246 $  254
Pandemic Influenza $  47 $ 25 $  9 $  223 $ 223
Rad/Nuc$ 10 $  5 $ 11 $ 82 $ 82
Ancillary$ 17 $  5 $ 11 $ 37 $ 28
Chemical$ 29 $ 17 $ 107 $ 26 $ 27
Burkholderia$ 1 $  1 $ 2 $  2 $ 2
FMS$ 0 $  0 $ 0 $ 0 $ 0

 

 

Data Table for Figure 9. Estimated FDA MCM Spending by Portfolio, FYs 2018–2022 (dollars in millions)

Portfolio FY 2018 FY 2019 FY 2020 FY 2021 FY 2022
CBRN MCM Base Funding (pre-MCMi) $48  $49  $57  $59  $61
Pandemic Influenza MCM$ 41 $  41 $ 44 $  45 $ 46
MCMi Annual$  25 $ 25 $  32 $  46 $ 48
Antimicrobial Resistance MCM$  23 $  22 $ 22 $ 23 $ 23
MCMi Multiyear$ 4 $ 4  $  -  $  -  $ 8
Transfer from No-Year Pandemic Influenza$  2  $  -  $  -  $  -  $  2

  • This page last reviewed: February 03, 2020